Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 8Leiomyoma 7Cushing Syndrome 4ACTH Syndrome, Ectopic 4Prostatic Neoplasms 3Pituitary Diseases 3Pituitary ACTH Hypersecretion 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Hirsutism 2Fallopian Tube Neoplasms 2Choristoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Adrenal Cortex Neoplasms 2Women With Mutations in the Breast Cancer Susceptibility Genes BRCA1,2 1Uterine Hemorrhage 1Sarcoma 1Neoplasms 1Meningioma 1Gulf War Illness 1Endometrial Stromal Tumors 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Intraductal, Noninfiltrating 1Breast Cancer Female 1

Interventions

pembrolizumab 91Gemcitabine 55Nivolumab 49Cisplatin 38atezolizumab 31Carboplatin 30avelumab 25enfortumab vedotin 23Docetaxel 23Magnetic Resonance Spectroscopy 18Ipilimumab 17Paclitaxel 16Mitomycin 15Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Transitional Cell × Mifepristone × Clear all
NCT02014337 2018-01-17

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Corcept Therapeutics

Phase 1 Completed
37 enrolled
BreastGenitourinaryGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡